Navigation Links
Scientists reduce behaviors associated with problem gambling in rats
Date:10/29/2013

With the help of a rat casino, University of British Columbia brain researchers have successfully reduced behaviours in rats that are commonly associated with compulsive gambling in humans.

The study, which featured the first successful modeling of slot machine-style gambling with rats in North America, is the first to show that problem gambling behaviours can be treated with drugs that block dopamine D4 receptors. The findings have been published in Biological Psychiatry journal.

"More work is needed, but these findings offer new hope for the treatment of gambling addiction, which is a growing public health concern," says Paul Cocker, lead author of the study and a PhD student in UBC's Dept. of Psychology. "This study sheds important new light on the brain processes involved with gambling and gambling addictions."

For the study, rats gambled for sugar pellets using a slot machine-style device that featured three flashing lights and two levers they could push with their paws. The rats exhibited several behaviours associated with problem gambling such as the tendency to treat "near misses" similar to wins.

Building on previous research, the team focused on the dopamine D4 receptor, which has been linked to a variety of behavioural disorders, but never proven useful in treatment. The study found that rats treated with a dopamine D4 receptor-blocking medication exhibited reduced levels of behaviours associated with problem gambling.

While findings suggest that blocking the D4 dopamine receptor may help to reduce pathological gambling behaviours in humans, the researchers note that further research is needed before the drugs can be considered a viable pharmaceutical treatment for pathological gambling in humans.


'/>"/>

Contact: Basil Waugh
basil.waugh@ubc.ca
604-822-2048
University of British Columbia
Source:Eurekalert

Page: 1

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. Queens scientists seek vaccine for Pseudomonas infection
3. Scientists produce eye structures from human blood-derived stem cells
4. American Society of Plant Biologists honors early career women scientists
5. Brandeis scientists win prestigious prize for circadian rhythms research
6. Scientists discover new method of proton transfer
7. Salk scientists open new window into how cancers override cellular growth controls
8. WileyChina.com - Now Featuring Bespoke Pages for China’s Life Scientists
9. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
10. UGA scientists reveal genetic mutation depicted in van Goghs sunflower paintings
11. Genetic mutation depicted in van Goghs sunflower paintings revealed by scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... The first study to analyze the complex ingredients in ... that these pop-into-the-mouth replacements for cigarettes in places where ... diseases and other problems. The report appears in ACS,s ... John V. Goodpaster and colleagues point out that the ...
... Mass. (March 16, 2011) Renowned cancer researchers Robert ... Hanahan, Director of the Swiss Institute for Experimental Cancer ... of Cancer," which has influenced the study of cancer ... decade. Published in January 2000, their original work, ...
... way the parasite that causes malaria reproduces could lead ... the disease. Scientists studying the disease have found ... from transmitting from person to person. Researchers at ... at a stage of its development in which it ...
Cached Biology News:New 'dissolvable tobacco' products may increase risk of mouth disease 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 3
(Date:7/30/2015)... San Diego , CA (PRWEB) , ... July ... ... Biopharma, announced the successful completion of a field clinical study of its canine ... being developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
(Date:7/29/2015)... SYDNEY , July 29, 2015 US-Australian ... NVGN ) today confirmed it is committed to progressing ... as soon as practicable and to ensure the Company ... Chief Executive Officer, Iain Ross , said the ... including the lead pre-clinical programs, discovery programs and academic ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... Enable CyberKnife Centers ... Demand for Radiosurgery, SUNNYVALE, Calif., Sept. 22 ... the field of radiosurgery,announced today that Oklahoma CyberKnife LLC, ... reduced treatment,planning and delivery times over the last two ...
... announced today,that its lead product ATIR(TM) has been ... Agency (EMEA) for the prevention of acute,Graft versus ... "Following the orphan drug designation granted by ... another important milestone in the development of,ATIR(TM) as ...
... China indicates that genetically modified cotton, altered to express the ... but also reduces pests among other nearby crops that have ... new ideas for controlling pests and maximizing crop yields in ... the journal Science on Friday, 19 September. ...
Cached Biology Technology:Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 2Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 3Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 4EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation 2GM crops protect neighbors from pests 2
...
Mouse Cell Line Slides...
Human Cell Line Slides...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
Biology Products: